The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
about
Inflammation, obesity, and the promise of immunotherapy for metabolic diseaseEmerging Therapies for Rheumatoid ArthritisAgonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial designClinical development of monoclonal antibody-based drugs in HIV and HCV diseasesCD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment?Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse ModelT lymphocytes and normal tissue responses to radiation.NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination.Mechanistic basis of immunotherapies for type 1 diabetes mellitusInterleukin-2/Anti-Interleukin-2 Immune Complex Attenuates Cardiac Remodeling after Myocardial Infarction through Expansion of Regulatory T Cells.How can we cure a heart "in flame"? A translational view on inflammation in heart failure.Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome.Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice.Human and mouse CD137 have predominantly different binding CRDs to their respective ligandsA Century of Radiation Therapy and Adaptive ImmunityDendritic cells enhance the antigen sensitivity of T cells.T-cell costimulatory blockade in organ transplantation.Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.CD28 Costimulation: From Mechanism to Therapy.Ischemic stroke: experimental models and reality.Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative.Delivering safer immunotherapies for cancer.Afterword: returning to philosophical foundations in research ethics.A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.Cancer immunotherapy trials: leading a paradigm shift in drug development.The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.Regulatory T cells in Acute and Chronic Kidney Diseases.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation.A non-conserved amino acid variant regulates differential signalling between human and mouse CD28.Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.CD28 between tolerance and autoimmunity: the side effects of animal models.The immunological synapse
P2860
Q27023490-650FB505-6BEC-4273-B16C-0E16F93E8A98Q28078943-F6D8894E-FDEE-4FE8-B492-154A6521329FQ28543054-CBA8DAD2-EBEE-4AFD-905E-D4D2474705E3Q34536782-04180425-51D8-44AF-AFF4-EB6B59AA526DQ35155979-6AA40A87-0087-4CBF-9E6B-16029C2404D1Q35641721-5F1A839B-4B61-454E-B923-F21EE4DD14B1Q35950889-839742C8-9F26-4B32-9A10-90B90B2EC34DQ36244299-BFFAAB0A-75A4-4A17-9CDE-B0364B7C134DQ36406293-A0F1DC1A-82DA-48D2-84CB-630193451830Q36698793-AA241EA1-96BE-4299-8E92-42D3BD5294E5Q36814572-1F9F0D3E-1194-4F12-8C5D-2230C6C034CDQ37004826-44534088-7248-4233-9959-A2957A564CE9Q37165647-EEDA77A5-1BF3-4D6E-A5F5-64F1EC937AEDQ37438906-47A3B610-358B-4CD0-A0EA-AE442D73406FQ37500368-54325FD4-0459-4C9A-B803-9119CE7D4C24Q37747153-53787E01-8BB9-43DF-A8BC-FD2D8E60B502Q38070158-4951F55D-31E4-4F51-A4A6-192BACBAFD1AQ38168010-9BD22888-3A5D-467F-ABC8-F127CE499047Q38236249-8204038A-EB3F-429F-A738-0930D4686B2AQ38837466-29801880-91BD-4664-B6E3-BC8AA7DD917CQ39073979-54886183-7A03-4845-A23C-60A8B8384DC5Q39213056-02D75116-277B-49C7-8BA5-1CDC02234623Q39330984-5CA8577A-95D8-41E2-95D0-DBB2BAD4BF05Q40632752-DB3425F8-D17F-486F-85E5-68EED0F8BDC2Q41668880-D86B3741-2CBC-4922-8554-247EC078DC1EQ42414063-0674EE8B-AFBC-4D61-AD16-38D4157041A0Q42560014-AFB8F817-D2F7-4A33-862E-CBDBF3DAEB4FQ45066685-CF0BD43C-8A38-4F73-946D-8A055DECD1C5Q45952214-CF72D206-4C11-42A9-8E16-B58940989F65Q47325431-DEC11A6C-B371-42F7-8187-313B1D67F14AQ47335259-FB6D0E0E-D5A6-4FA5-89A5-1EEAFC46AC9AQ49426485-F8D30054-BBB4-47A1-A797-90C0A229BE56Q55174942-F81480D5-7811-4F12-89E8-6490514F7F42Q55243180-BDFB889C-6EFF-4C1F-A225-87CF297051DBQ55286510-36BDC510-B5E9-432F-B762-859DC82CB00EQ57961866-37E4A9E9-6FC9-42B6-BF76-29BC56337E50
P2860
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@en
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@nl
type
label
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@en
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@nl
prefLabel
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@en
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@nl
P2860
P356
P1476
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
@en
P2093
Thomas Hünig
P2860
P304
P356
10.1038/NRI3192
P577
2012-04-10T00:00:00Z